Year 2014 in ReviewHere is the second installment of interesting studies that effected OBGYN and women’s health in 2014. See our blog post for Dec. 8, 2014 to read part 1.

Long-acting reversible contraception for adolescents – The etonogestrel implant and intrauterine device (IUD) is now recommended by The American Academy of Pediatrics as the first-line contraceptive options for adolescents. These are two types of long-acting reversible contraception (LARC).

Secura GM, Madden T, McNicholas C, et al. Provision of no-cost, long-acting contraception and teenage pregnancy. N Engl J Med 2014; 371:1316.

Levonorgestrel IUD in endometrial carcinoma prevention – The results of this study suggests that the levonorgestrel-releasing intrauterine device (LNg-IUD) has a potential preventive, as well as therapeutic, role in preventing incidence of endometrial carcinoma in women diagnosed with abnormal uterine bleeding (AUB).

Soini T, Hurskainen R, Grénman S, et al. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol 2014; 124:292.

KEEPS hormone therapy trial in newly menopausal women – The Women’s Health Initiative,  now suggest that use of menopausal hormone therapy (MHT) in the early menopausal years is not associated with excess coronary heart disease risk.

Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 2014; 161:249.

Pelvic examination in asymptomatic women – The American College of Physicians (ACP) and The American College of Obstetricians and Gynecologists have controversy over the guidelines issued by the ACP pertaining to screening pelvic exams in asymptomatic, non-pregnant, adult women.

Qaseem A, Humphrey LL, Harris R, et al. Screening pelvic examination in adult women: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2014; 161:67.

http://www.acog.org/About-ACOG/News-Room/College-Statements-and-Advisories/2014/ACOG-Practice-Advisory-on-Annual-Pelvic-Examination-Recommendations (Accessed on July 01, 2014).

Topical lidocaine for dyspareunia after treatment for breast cancer – Women who have been treated for breast cancer often suffer from dyspareunia (painful intercourse). In a small trial, it was shown that topical lidocaine treatment proved effective relief for women who suffer from dyspareunia.

Goetsch MF, Lim JY, Caughey AB. Locating pain in breast cancer survivors experiencing dyspareunia: a randomized controlled trial. Obstet Gynecol 2014; 123:1231.

Related Post